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Abstract 
Background. In 2016, the MAGNIMS network proposed modifications to the MRI criteria 
to define dissemination in space (DIS) and time (DIT) for the diagnosis of multiple sclerosis (MS) 
in clinically isolated syndrome (CIS) patients. Changes to DIS definition included removal of 
distinction between symptomatic and asymptomatic lesions; increasing to three the number of 
lesions needed to define periventricular (PV) involvement; combining cortical (CL) and 
juxtacortical lesions (JC); and adding the optic nerve (ON). For DIT, removing the distinction 
between symptomatic and asymptomatic lesions was suggested. 
We compared the performance of the McDonald 2010 and MAGNIMS 2016 criteria for MS 
diagnosis in a large multicentre cohort of CIS patients to provide evidence to guide future revisions 
of MS diagnostic criteria. 
Methods. Between 1995 and 2017, brain and spinal cord MRI and optic nerve assessments 
were collected from 368 patients with typical CIS suggestive of MS studied less than 3 months 
from clinical onset in eight European centres. Occurrence of a second clinical attack (clinically 
definite -CD- MS) was recorded during the follow-up. MRI criteria performance for DIS, DIT and 
DIS plus DIT was evaluated using a time-dependent receiver operating characteristic curve 
analysis, with CDMS at months (M) 36 and 60 as the outcome.  
Findings. At the last evaluation (median=50.0 months, IQR=27.0-78.4), 189/368 (51%) 
patients developed CDMS. At M36, both DIS criteria showed high sensitivity (McDonald 
2010=0.91, 95% CI=0.85-0.94; MAGNIMS 2016=0.93, 0.88-0.96), similar specificity (0.33, 95% 
CI 0.25-0.42; 0.32, 0.24-0.41), and similar area under the curve (AUC; 0.62, 95% CI 0.57-0.67; 
0.63, 0.58-0.67). Performance of criteria was not affected by inclusion of symptomatic lesions 
(sensitivity 0.92, 0.87-0.96; specificity 0.31, 0.23-0.40; AUC 0.62, 0.57-0.66) or CL (sensitivity 
0.92, 0.87-0.95; specificity 0.32, 0.24-0.41; AUC 0.62, 0.57-0.67). Our findings suggested that 
requiring three PV lesions might result in slightly lower sensitivity (0.85, 0.78-0.90), slightly higher 
specificity (0.40, 0.32-0.50) and similar AUC (0.63, 0.57-0.68). Our findings suggested that 
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inclusion of ON evaluation might result in similar sensitivity (0.92. 0.87-0.96) and slightly lower 
specificity (0.26, 0.18-0.34) and AUC (0.59, 0.55-0.64). AUCs for DIT (McDonald 2010=0.61, 
0.55-0.67; MAGNIMS 2016=0.61, 0.55-0.66) and for DIS plus DIT (McDonald 2010=0.62, 0.56-
0.67; MAGNIMS 2016=0.64, 0.58-0.69) were also similar.  
Interpretation. For CDMS development, MAGNIMS 2016 criteria have similar accuracy to 
McDonald 2010 criteria. Inclusion of symptomatic lesions is expected to simplify the clinical use of 
MRI criteria without reducing accuracy, while our findings suggest that needing three lesions to 
define PV involvement might slightly increase specificity. Future revisions of MS diagnostic 
criteria should consider these two factors. 
Funding. UK MS Society; National Institute for Health Research, UCL Hospitals Biomedical 
Research Centre; Dutch Foundation for MS Research.
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Research in context 
Evidence before this study 
After the proposal of the MAGNIMS 2016 criteria, we searched PubMed for original research 
articles and reviews evaluating MRI criteria for the diagnosis of multiple sclerosis (MS) published 
from January 1, 1979 to October 31, 2017, with the terms “MRI”, “clinically isolated syndrome”, 
“multiple sclerosis”, “second attack”, “relapse”, “conversion”, “McDonald criteria”, “diagnosis”, 
“differential diagnosis”, “white matter”, “lesions”, “symptomatic lesions”, “periventricular”, 
“brainstem”, “cerebellar”, “cortical lesions”, “brain”, “spinal cord”, “optic nerve”, “visual evoked 
potentials”, “disease dissemination in space”, “disease dissemination in time”, and “high field”. 
Only papers published in English were considered. We identified several studies which evaluated 
different MRI criteria, even though they were often limited by their small sample size, their 
retrospective design, their short follow-up, the presence of confounding factors (e.g., selection bias, 
treatment effects, etc.) and the fact that they assessed only single items of the criteria recently 
proposed. 
 
Added value of this study 
By evaluating a large multicentre cohort of patients with a clinically isolated syndrome (CIS) 
suggestive of MS, we compared the MAGNIMS 2016 criteria and the McDonald 2010 criteria for 
the development of clinically definite MS. Overall, our results suggest that the MAGNIMS 2016 
criteria give similar performance compared to the McDonald 2010 criteria.  
To our knowledge, this is the first complete study which evaluates the performance of the recently 
proposed MAGNIMS 2016 criteria in a large multicentre cohort of CIS patients. In addition to the 
global performance of the MAGNIMS 2016 criteria, we also investigated how the introduction of 
each of their proposed modifications into the McDonald 2010 criteria affected the performance.  
Implications of all the available evidence 
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Accurate criteria in the diagnostic work-up of CIS patients are of critical importance not only to 
enable an early diagnosis of MS, thus allowing treatment to start sooner, but also to minimise the 
risk of misdiagnosis and overdiagnosis.  
This study provides relevant pieces of information regarding the rationale for and performance of 
the MAGNIMS 2016 criteria. MAGNIMS 2016 criteria showed a similar overall diagnostic 
accuracy compared to McDonald 2010 criteria, and gave higher adjusted hazard ratio(aHR) for the 
development of clinically definite MS. 
From the analyses of each proposed modification to the MRI criteria of the McDonald 2010 criteria, 
our results suggest that inclusion of symptomatic lesions and three lesions to define periventricular 





In 2001, an international panel of multiple sclerosis (MS) specialists formally included MRI 
in the MS diagnostic criteria to provide objective evidence for disease dissemination in space (DIS) 
and time (DIT) and to exclude alternative diagnoses.1 Since their introduction, these criteria have 
been modified to simplify them, to clarify specific aspects (e.g., inclusion of spinal cord [SC] MRI 
findings) and to enable earlier diagnosis of MS,2-4 thus allowing treatment to start sooner. Since the 
last revision of these criteria (the McDonald 2010 criteria),3 new data about the application of MRI 
for MS diagnosis have become available, and there have been improvements in MRI technology. 
This led members of the MAGNIMS network to organise an international workshop in 2015, to 
review recent imaging findings and to establish their contribution to MS diagnosis, proposing 
evidence-based modifications to the MRI diagnostic criteria. This, together with expert consensus, 
resulted in the MAGNIMS 2016 criteria.5  
Modifications to the DIS criteria5 were: 1) the removal of any distinction between 
symptomatic and asymptomatic lesions;6, 7 2) increasing from 1 to 3 in the number of lesions 
needed to establish periventricular (PV) involvement;8-13 3) combining cortical lesions (CL) 
(confined to the cortex without involving the underlying subcortical white matter [WM]) and 
juxtacortical lesions (JC) (contiguous to the gray matter [GM], and mixed WM/GM) to expand the 
concept of JC involvement;14 and 4) including the optic nerve (ON) as an additional location for 
DIS definition.15-17 Removing the distinction between symptomatic and asymptomatic lesions and 
inclusion of any new/active lesion were suggested for DIT criteria. 
This study compares MAGNIMS 20165 and the McDonald 20103 criteria in a large 
multicentre cohort of patients with a clinically isolated syndrome (CIS) suggestive of MS, collected 
within the MAGNIMS network to evaluate their performance in the diagnosis of clinically definite 
(CD) MS. Each individual modification from the MAGNIMS criteria5 was also assessed to 
investigate its influence on the diagnostic performance and thus its potential contribution to future 




Ethics committee approval. Approval was received from the local ethical standards committee 
and written informed consent was obtained from all subjects at the time of data acquisition. Because 
the study was based on existing data, with no additional burden on the patient, no further approval 
from the institutional review board was needed. 
Patients. This project was run within the European MAGNIMS network 
(http://www.magnims.eu) and involved eight highly specialised MS centres with expertise in 
neuroimaging (see Supplementary Methods). The study design was similar to that of previous 
studies aimed at assessing the performance of MS diagnostic criteria.14, 18, 19 Centres were asked to 
identify CIS patients recruited into prospective MRI and clinical follow-up (FU) studies from June 
16, 1995 to January 27, 2017 with: (a) age between 16 and 60 years; (b) a first CIS suggestive of 
CNS demyelination;20 (c) a clinical presentation typical for a relapsing-remitting MS;21 (d) a 
complete neurological examination; (e) a baseline brain and SC MRI scan obtained <3 months from 
the clinical onset; and (f) a FU brain scan obtained <12 months from CIS onset. Development of 
CDMS was defined as the occurrence of a second clinical event attributable to demyelination 
lasting more than 24 hours and after an interval of at least one month from the first attack, with 
evidence of two separate lesions. Time to CDMS was calculated as the interval between the onset of 
the first and second events. 
Appropriate investigations were carried out as necessary to exclude alternative diagnoses, the 
presence of comorbidities (psychiatric or other neurological disorders), and previous clinical events. 
The following information was also collected: age at CIS onset, sex, type of onset, EDSS, 
presence of oligoclonal bands (OCB) (if cerebrospinal fluid examination had been performed),date 
of initiation and types of disease-modifying treatment (if applicable). 
MRI analysis. Details of the MRI acquisition are reported in the Supplementary Methods. All 
images were assessed by consensus by two experienced observers (PP and MAR), blinded to the 
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patients’ identity and MS status at the Neuroimaging Research Unit (Milan, Italy). Brain WM 
lesions were identified on DE/FLAIR images and were defined as hyperintensities involving at least 
3 voxels, present on at least two slices and visible on two different sequences (e.g., FLAIR and T2 
or proton density and T2). Total number of WM lesions, number of PV (in direct contact with the 
ventricular system), JC, and posterior fossa (PF) lesions (located in the brainstem and/or 
cerebellum) were evaluated. CL and JC lesions identified from double inversion recovery (DIR) 
(when available) and T2/FLAIR sequences, where combined to expand the definition of JC 
involvement. Gd-enhancing lesions were identified on post-contrast T1-weighted scans. 
Hyperintense SC lesions were counted.  
To evaluate the effects of symptomatic lesions, if a subject had a brainstem or SC syndrome, 
we counted lesions both including and excluding those present in symptomatic regions. 
ON involvement was evaluated using MRI (presence of a ON lesion) and/or visual evoked 
potentials (VEP) (presence of an increased latency and/or a decreased amplitude and/or an 
asymmetry between the eyes). 
From the FU MRI scans, the numbers of new T2-hyperintense and Gd-enhancing lesions 
were quantified. 
DIS and DIT criteria. On baseline MRI scans, the following DIS criteria were assessed (see 
Supplementary Table 1): 1) McDonald 2010 criteria;3 2) MAGNIMS 2016 criteria;5 3) modified 
DIS criteria 1: McDonald 2010 criteria modified to include symptomatic lesions; 4) modified DIS 
criteria 2: McDonald 2010 criteria modified to change to 3 the minimum number of lesions 
necessary to define PV involvement; 5) modified DIS criteria 3: McDonald 2010 criteria modified 
to combine CL and JC; 6) modified DIS criteria 4: McDonald 2010 criteria modified to include ON 
involvement as an additional location for the definition of DIS. 
On baseline and FU MRI, DIT was defined according to 1) the McDonald 2010 criteria3 and 
2) the MAGNIMS 2016 criteria5 (Supplementary Table 1). 
The fulfilment of DIS plus DIT criteria for all DIS criteria was also assessed.  
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Statistical analysis. Cumulative/dynamic time-dependent receiver operating characteristic 
(ROC) curve analysis22 for censored survival data was applied to assess the performance of the MRI 
criteria for DIS, DIT and DIS plus DIT, using the clinical status (CDMS or CIS) over time as 
outcome. Sensitivity, specificity, accuracy, positive and negative predictive values at months 36 
(M36) and 60 (M60) were calculated. Bias-corrected and accelerated bootstrap method23 was used 
to estimate 95% confidence intervals (CIs).  
The cumulative risk of CDMS development from the first clinical event up to the last 
available FU was represented using Kaplan-Meier survival curves (patients censored according to 
their FU). Extended Cox regression models using time to CDMS as the outcome and adjusted for 
age (continuous), sex (binary), treatment (binary, time-dependent, i.e., treatment effects were 
modeled considering the time when a patient started any treatment), disease onset type (optic 
neuritis vs others), and presence of OCB (binary) were performed to obtain adjusted hazard ratios 
(aHRs) and 95% CIs. A shared gamma-frailty term was also included to address centre effects, 
accounting for unobserved heterogeneity and statistical dependence between clustered time-to-event 
data.24 Based on a bootstrap resampling technique, a test for the hypothesis of no difference 
between aHRs for McDonald 2010 criteria and other MRI criteria was performed. Similar models 
including a specific interaction term were estimated to explore possible interaction between MRI 
criteria and treatment, type of onset or the presence of OCB.  
Role of the funding source. The funding sources had no role in study design, collection, 
analysis, and interpretation of data; writing of the report; or the decision to submit the paper for 
publication. The corresponding author had full access to all data in the study and had final 
responsibility for the decision to submit the paper for publication. 
 
Results 
From an initial selection of 571 CIS patients, the final cohort comprised 368 CIS patients 
fulfilling all study inclusion criteria (see Figure 1 for study flow chart).  
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Table 1 summarises the main baseline demographic, clinical and MRI findings of the CIS 
patients included.  
For the final cohort, MRI had been obtained at 1.0 Tesla (15 [4%] patients), 1.5 Tesla (243 
[66%] patients) or 3.0 Tesla (110 [30%] patients). 
Assessment of ON involvement was performed in 241 (65%) CIS patients: 216 with a 
monofocal onset (97 optic neuritis, 42 brainstem/cerebellar syndrome, 57 SC syndrome and 20 
hemispheric) and 25 with multifocal onset. This assessment was based on VEP in 219/241 (91%) 
patients, ON MRI in 3/241 (1%) patients and both VEP and ON MRI in 19/241 (8%) patients.  
At baseline, 41 (11%) CIS patients showed no lesions on brain MRI (6 of them presented 
lesions at SC MRI), while 195 (53%) had no SC lesions.  
One-hundred and twenty-eight (35%) patients had a brainstem/cerebellar or SC syndrome at 
onset, and at least one T2-hyperintense lesion in the symptomatic region. ON involvement was 
found in 130/241 (54%) patients. 
At the last evaluation (median=50.0 months; IQR27.0-78.4 months), 189 (51%) CIS patients 
had a second clinical episode (median time to conversion=10.9 months, IQR=5.0-24.6) and 184 
(50%) developed new T2 or Gd-enhancing lesions. During the FU, 157 (43%) patients started 
disease-modifying drugs and 50 (32%) of them did not develop CDMS. 
The performance of the different combined diagnostic criteria is shown in Table 2, while 
Figure 2a and Supplementary Figure 1a show the area under the curve (AUC) over time, up to 10 
years, from disease onset of the McDonald 2010 and MAGNIMS 2016 criteria according to the 
development of CDMS. The main results from these analyses at M36 are: 
1) considering DIS alone, both the McDonald 2010 and MAGNIMS 2016 criteria had high 
sensitivity (0.91 and 0.93), similar specificity (0.33 and 0.32) and similar AUC (0.62 and 0.63); 
2) all modified DIS criteria showed similar performance compared to the McDonald 2010 
criteria (sensitivity ranging from 0.85 to 0.92, specificity from 0.26 to 0.40, AUC from 0.59 to 
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0.63). Our results suggest that the use of 3 PV lesions resulted in slightly lower sensitivity (0.85) 
and slightly higher specificity (0.40), while ON evaluation had the lowest specificity (0.26); 
3) the two DIT criteria investigated showed similar performance (sensitivity=0.78 and 0.80, 
specificity=0.44 and 0.42, AUC=0.61 for both); 
4) for both McDonald 2010 and MAGNIMS 2016 criteria, fulfilling DIS plus DIT gave 
similar sensitivity (0.73 and 0.77), specificity (0.50 for both) and AUC (0.62 and 0.64); 
5) DIS plus DIT with all modified DIS criteria gave similar performance compared to the 
McDonald 2010 criteria (sensitivity ranging from 0.70 to 0.76, specificity from 0.48 to 0.55, AUC 
from 0.61 to 0.63). 
Similar results were found considering CDMS at M60 as the outcome (Table2, Figure 2a and 
Supplementary Figure 1a). Given the high percentage of patients with optic neuritis at onset, the 
performance of the McDonald 2010 and MAGNIMS 2016 criteria according to type of onset (optic 
neuritis vs other types of onset) was also investigated (Supplementary Table 2 and Supplementary 
Figure 2). Both sets of criteria were more sensitive (CIS with optic neuritis: McDonald 2010=0.87, 
95% CI=0.77-0.94 and MAGNIMS 2016=0.90, 95% CI=0.80-0.95; CIS with other types of onset 
McDonald 2010=0.93, 95% CI=0.86-0.97 and MAGNIMS 2016=0.95, 95% CI=0.89-0.99) and less 
specific (CIS with optic neuritis: McDonald 2010=0.44, 95% CI=0.32-0.56 and MAGNIMS 
2016=0.39, 95% CI=0.27-0.52; CIS with other types of onset McDonald 2010=0.21, 95% CI=0.12-
0.33 and MAGNIMS 2016=0.25, 95% CI=0.14-0.37) in patients without optic neuritis, but this 
difference was less pronounced for the MAGNIMS 2016 criteria. 
Figure 2b and Supplementary Figure 1b show the Kaplan-Meier curves used to estimate the 
cumulative risk of CDMS development using DIS only, DIT only or DIS plus DIT from the 
McDonald 2010 and MAGNIMS 2016 criteria, while the aHRs from the extended Cox regression 
models are shown in Table 3. The cumulative risk of CDMS development was similar for the 
McDonald 2010 and MAGNIMS 2016 criteria. A lack of fulfilment of the MAGNIMS 2016 criteria 
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was associated with a higher conversion-free survival than was the case for the McDonald 2010 
criteria (Figure 2b).  
aHRs were higher for the MAGNIMS 2016 compared to the McDonald 2010 
criteria,(aHR=4.43 and 3.48, for DIS only; aHR=2.95 and 2.52, for DIS plus DIT, p<0.0001 for all), 
but not significantly different (p=0.12 for DIS only; p=0.08 for DIS plus DIT) (Table 3). Similar 
significant aHRs, not different from those of the McDonald 2010 criteria, were found for the other 
modified criteria evaluated (aHRs ranging from 3.13 to 3.66 for DIS only and from 2.54 to 2.60 for 
DIS plus DIT, p<0.0001 for all) (Table 3). 
The aHRs of the criteria were not affected by disease onset type, presence of OCB or 
treatment (Supplementary Table 3). 
 
Discussion 
Thanks to improvements in MRI technology and its increasing application in MS, new 
evidence for the use of MRI in the diagnostic work-up of patients with a suspicion of MS has 
emerged since the publication of the McDonald 2010 criteria,3 and was considered in the 
MAGNIMS 2016 criteria.5 Since their publication, different aspects proposed in the MAGNIMS 
2016 consensus guidelines have been examined. A recent study of 170 CIS patients25 compared the 
performance of the McDonald 2010 and MAGNIMS 2016 criteria for DIS only, considering the 
clinical status at heterogeneous FU durations (at least two years) as the outcome. Additionally, SC 
and ON evaluations were performed only in those patients with clinical involvement of these 
regions. As a consequence, a proper validation of these criteria has so far been lacking. 
By evaluating a large multicentre cohort of patients experiencing a typical CIS, we found that 
the performance of the McDonald 2010 and MAGNIMS 2016 criteria was similar considering 
CDMS conversion at M36 and M60. Specifically, both criteria showed high sensitivity and 
accuracy and similar specificity. For both sets of criteria, specificity was lower than that of previous 
studies that evaluated the diagnostic performance of the McDonald 2010 criteria.6, 7, 13, 19 Several 
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factors may help to explain the current findings, including the different FU durations,6, 13 the 
methods used for the statistical analysis (using a time-to-event analysis in the current study), and the 
influence of treatment, which may have delayed or prevented the occurrence of the second attack 
during the study period.  
Survival probability analyses confirmed that the two sets of criteria had similar performance. 
Compared to the McDonald 2010, the MAGNIMS 2016 DIS criteria had a higher aHR, although 
not significantly different, which agrees with the higher conversion-free survival in CIS patients not 
fulfilling these criteria and the suggestion of slightly higher negative predictive values (0.79, 95% 
CI 0.67-0.87, vs 0.83, 0.71-0.91, at M36). 
Quite similar results were obtained when the combination of DIS plus DIT for the two sets of 
criteria were tested. 
In addition to the global performance of the MAGNIMS 2016 criteria, we also investigated 
how the introduction of each of their proposed modifications into the McDonald 2010 criteria 
changed the final performance. The purpose of this approach was to see whether the overall 
specificity of the McDonald 2010 criteria could be increased, thus minimising overdiagnosis.26 
Consistent with some recent studies,6, 7 our study provides further support for the inclusion of 
lesions in the symptomatic region in CIS patients with a brainstem or SC onset, since this did not 
affect the performance of DIS and DIT diagnostic criteria. The definition of what is symptomatic 
may be extremely challenging, and thus the removal of the distinction between symptomatic and 
asymptomatic lesions is likely to simplify the clinical implementation of these criteria. Moreover, 
since CIS patients with a single symptomatic lesion have a high risk of CDMS conversion,6, 7 the 
inclusion of these lesions may have clinical relevance in predicting a diagnosis of MS in these 
patients.  
According to the MAGNIMS 2016 criteria, a single PV lesion is not deemed sufficient to 
indicate involvement of the PV region. Indeed, PV lesions have been described in many other 
neurological conditions, which often enter the differential diagnosis of MS, including migraine,9, 10 
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cerebrovascular diseases and other inflammatory disorders.12 Moreover, a threshold of three or 
more PV lesions was found to be the most accurate for predicting CDMS conversion,8 and the 
presence of at least 3 PV lesions predicted CDMS in large cohorts of CIS patients,11 and in a CIS 
cohort with SC onset. In a recent study, 3 PV lesions improved specificity in older CIS patients.27 In 
line with this evidence and with that of a recent 15-year FU study,13 our results suggested that the 
use of 3 lesions to define PV involvement slightly reduced sensitivity (0.85 vs 0.91 at M36), but 
slightly increased specificity (0.40 vs 0.33 at M36), without affecting diagnostic accuracy. Given 
the increased risk of misdiagnosis due to an oversimplification of MS diagnostic criteria, there is the 
need to consider features which could be more distinctive for this condition compared to other 
diseases.26 Our findings suggest that this criterion might improve the specificity of the MRI 
diagnostic criteria, reducing misdiagnosis and also representing a possible prognostic factor.  
CLs are a distinctive feature of MS patients from the beginning of the disease,14 and have 
not been detected in patients with other neurological conditions, including neuromyelitis optica and 
migraine. As a consequence, including CL assessment in the diagnostic algorithm of CIS patients, is 
likely to increase specificity, as suggested by a single-centre study14 and recently confirmed by a 
multi-centre investigation.28 Despite this, acquiring MR images that depict CLs is technically 
challenging, and there are no standardised sequences for this task. Consequently, MAGNIMS 
guidelines5 recommended using the combined term CL/JC to expand the concept of JC 
involvement. In our analysis, inclusion of CLs evaluation in the subgroup of CIS patients (45%) 
with DIR acquisition did not significantly influence DIS criteria performance, and only four 
additional patients fulfilled the DIS criteria.  
The effect of the inclusion of the ON as an additional site for DIS fulfillment was also 
investigated in those patients who had VEP or optic nerve MRI evaluations. Clearly, since this 
study was not pre-planned to include proper investigation of this region, the data were available for 
only about half of the patients, with a relatively heterogeneous assessment of neurophysiology, 
MRI, or both. Optic neuritis is the first manifestation of MS in up to 30% of CIS patients,20 who 
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have generally been considered to have a lower risk of developing MS. Despite this, recent 
evidence has demonstrated that the concomitant presence of WM lesions,15, 17 early new lesion 
formation16 or cerebrospinal fluid OCB17 increases the risk of developing MS in patients with this 
type of presentation. Our findings suggested that the inclusion of ON assessment in the definition of 
DIS might slightly decrease specificity (0.26 vs 0.33 at M36), which is expected whenever 
additional criteria are included. An assessment of whether the combination of ON involvement with 
different DIS criteria (e.g., presence of 3 PV lesions) or a change in the number of sites needed to 
define DIS (e.g., from 2 to 3) modifies performance of diagnostic criteria was beyond the scope of 
the present investigation. Consequently, studies aimed at validating MRI and neurophysiological 
measures of ON involvement in fulfilling diagnostic criteria in support of MS should be undertaken.  
Given the high percentage of patients with optic neuritis, we also explored whether this type 
of presentation gives different performance of the criteria. Both sets of criteria were more sensitive 
and less specific in patients without than those with optic neuritis. However, the difference of 
performance was less pronounced for MAGNIMS 2016 criteria.  
This study has some limitations. First, our CIS patients were recruited in highly specialised 
centres, possibly resulting in the selection of patients at higher risk of conversion to CDMS (51%), 
as also suggested by their high median lesion number (median=11). Moreover, our cohort included 
only patients with a typical syndrome suggestive of MS and without comorbidities, and thus the 
performance of MRI criteria in CIS patients with atypical features, with other diseases mimicking 
MS or with other concurrent diseases was not evaluated. However, it should be borne in mind that 
this is the type of patients for whom the criteria have been proposed and that application of MS 
criteria outside this typical scenario is discouraged by the International Panel.1-4 
Secondly, because we needed a long enough FU for the analysis, the data were collected 
retrospectively. However, all patients included are part of ongoing studies run by the participating 
centres, and are therefore representative of the current population of CIS patients in Europe, 
including the type of presentation and policies for early treatment initiation (which, however, 
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showed no effect in the interaction analysis). As a consequence, we believe that our results are 
generalizable to CIS patients attending the majority of MS clinics. Thirdly, due to the multicentre 
setting, MR images were acquired using different field strengths (from 1.0 to 3.0 Tesla) and MRI 
parameters (e.g. slice thickness). This allowed us to evaluate the MRI criteria in a situation close to 
a clinical setting. Although high-field MRI allows the detection of higher number of WM lesions in 
CIS and MS patients,29 it has been demonstrated that field strength does not influence significantly 
fulfilment of DIS and DIT criteria.30 Nevertheless, to take all these differences into account, 
survival analyses were performed after correcting for centre.  
Overall, this study provides important pieces of information regarding the application of the 
recently proposed MAGNIMS 2016 criteria for MS diagnosis. Our findings suggest that the 
MAGNIMS 2016 criteria perform similarly to the McDonald 2010 criteria. Among the different 
modifications proposed, our results support removal of the distinction between symptomatic and 
asymptomatic lesions, which simplifies the clinical use of MRI criteria, and suggests that further 
consideration of increasing to 3 the number of lesions needed to define PV involvement is 
warranted, as this seemed to slightly increase specificity. Further effort is still necessary to improve 
CL assessment and more studies should be performed to better evaluate the influence of including 
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Table 1. Main baseline demographic, clinical, and MRI findings from the final cohort of clinically 




Demographic details  
Number (%) of 
• Men  




Median age at onset (IQR) [years]  32.5 (26.0-39.2) 
Clinical details  
Median disease duration at baseline MRI (IQR) [months]  1.8 (0.8-2.8) 
Median EDSS at baseline (IQR)  1.5 (1.0-2.0) 
Clinical presenting symptom(s) (%):  
Monofocal 
• Optic neuritis  
• Brainstem/cerebellar syndrome  
• Spinal cord syndrome 




• 169/340 (50%) 
• 61/340 (18.0%) 
• 79/340 (23%) 
• 31/340 (9%) 
28 (8%) 
Number (%) of patients with CSF analysis 256 (70%) 
Number (%) of patients with oligoclonal bands 176/256 (69%) 
Number (%) of patients receiving treatment at FU 157 (43%) 
CDMS at 12 months from onset (%) 99 (27%) 
CDMS at FU (%) 189 (51%) 
Median time to CDMS (IQR) [months]  10.9 (5.0-24.6) 
Median FU duration in not converters (IQR) [months] 36.2 (15.1-60.5) 
MRI details  
Baseline number (%) of patients with lesions (brain and 333 (90%) 
23 
cord) 
Median lesion number (IQR) 11 (4-25) 
Median time to FU MRI (IQR) [months] 6.4 (5.1-11.3) 
MRI criteria  
Baseline number (%) of patients with ≥ 1 PV lesion 292 (79%) 
Baseline number (%) of patients with ≥ 3 PV lesions 231 (63%) 
Baseline number (%) of patients with ≥ 1 JC lesion 259 (70%) 
Baseline number (%) of patients with ≥ 1 CL//JC 266 (72%) 
Baseline number (%) of patients with ≥ 1 PF lesion 165 (45%) 
Baseline number (%) of patients with ≥ 1 SC lesion 173 (47%) 
Baseline number (%) of patients with symptomatic 
lesions* 
128 (35%) 
Baseline number (%) of patients with ≥ 1 Gd-enhancing 
lesion 
150 (41%) 
Number (%) of patients with ≥ 1 new T2/Gd-enhancing 
lesion at FU MRI  
184 (50%) 
 
*for patients with a brainstem or spinal cord syndrome.  
Abbreviations: CIS=clinically isolated syndrome; MRI=magnetic resonance imaging; 
IQR=interquartile range; EDSS=Expanded Disability Status Scale; CSF=cerebrospinal fluid; 
FU=follow-up; CDMS=clinically definite multiple sclerosis; PV=periventricular; JC=juxtacortical; 
CL=cortical lesion; PF=posterior fossa; SC=spinal cord; Gd=gadolinium. See text for further 
details.  
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Table 2. Performance of the different combined MRI criteria for dissemination in space (DIS), dissemination in time (DIT) and DIS plus DIT for 





























































































































































































































































































































































Abbreviations: MRI=magnetic resonance imaging; CI=confidence interval; AUC=area under the curve; PPV=positive predictive value; 
NPV=negative predictive value; DIS=dissemination in space; DIT=dissemination in time; PV=periventricular; CL=cortical lesion; JC=juxtacortical; 
ON=optic nerve; M=month. 
Modified DIS criteria 1: McDonald 2010 criteria modified to include symptomatic lesions; modified DIS criteria 2: McDonald 2010 criteria 
modified to change to 3 the minimum number of lesions necessary to define PV involvement; modified DIS criteria 3: McDonald 2010 criteria 
modified to combine CL and JC; modified DIS criteria 4: McDonald 2010 criteria modified to include ON involvement as an additional location for 




Table 3. Adjusted hazard ratios (aHRs) with their corresponding 95% confidence intervals (CI) and 
a bootstrap-based comparison with the McDonald 2010 criteria. aHRs were obtained from extended 
Cox regression models using time to clinically definite multiple sclerosis (CDMS) as the outcome 





































































Abbreviations: aHR=adjusted hazard ratios; CI=confidence interval; DIS=dissemination in space; 
DIT=dissemination in time; PV=periventricular; CL=cortical lesion; JC=juxtacortical; ON=optic 
nerve.  




Figure 1. Study flow chart. See text for further details. Abbreviations: NMOSD=neuromyelitis 
optica spectrum disorder. 
 
Figure 2. (a) Overall accuracy of the McDonald 2010 (red line) and MAGNIMS 2016 (blue line) 
criteria determined by the area under the curve (AUC) over time, up to 10 years, from disease onset, 
to the development of clinically definite multiple sclerosis (CDMS), considering dissemination in 
space (DIS) only or DIS plus dissemination in time (DIT). (b) Kaplan-Meier curves showing the 
survival probability estimates of not developing CDMS up to 10 years from disease onset 
considering DIS only or DIS plus DIT according to the McDonald 2010 and MAGNIMS 2016 
criteria. See text for further details. Abbreviations: CI=confidence interval. 
 
 
 
 
 
